CAS NO: | 865759-25-7 |
规格: | ≥98% |
包装 | 价格(元) |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
1g | 电议 |
2g | 电议 |
Molecular Weight (MW) | 357.38 |
---|---|
Formula | C18H20FN5O2 |
CAS No. | 865759-25-7 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 71 mg/mL (198.7 mM) |
Water:<1 mg/mL | |
Ethanol: 3 mg/mL warmed (8.4 mM) | |
Solubility (In vivo) | Chemical Name: (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile. InChi Key: IWYJYHUNXVAVAA-OAHLLOKOSA-N InChi Code: InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3/t15-/m1/s1 SMILES Code: N#CC1=CC=C(F)C=C1CN(C(N2C)=O)C(N3C[C@H](N)CCC3)=CC2=O |
Synonyms | SYR 472; Trelagliptin; SYR-472; SYR472; trade name: Zafatek. |
In Vitro | In vitro activity: Trelagliptin (also known as SYR-472) is a potent, highly selective, long-acting DPP-4 (dipeptidyl peptidase-4) inhibitor under development by Takeda for the treatment of type 2 diabetes (T2D).. Once-weekly Trelagliptin treatment produced clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. It was well tolerated and might be a new treatment option for patients with this disease. Trelagliptin was approved in Japan for the treatment of type 2 diabetes mellitus (T2DM). |
---|---|
In Vivo | Trelagliptin improves glycaemic control by inhibition of DPP-4 activity. |
Animal model | |
Formulation & Dosage | |
References | Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32. |